Sangamo Therapeutics Inc., a genomic medicine company, has announced that its investigational gene therapy, isaralgagene civaparvovec, has received significant regulatory designations from various health authorities. The U.S. Food and Drug Administration (FDA) has granted the therapy Orphan Drug, Fast Track, and RMAT designations, while the European Medicines Agency has provided Orphan Medicinal Product designation and PRIME eligibility. Additionally, the U.K. Medicines and Healthcare products Regulatory Agency has included it in the Innovative Licensing and Access Pathway. These designations are expected to expedite the development and potential approval of the therapy, which aims to treat Fabry disease. Sangamo is preparing a Biologics License Application $(BLA.AU)$ submission for 2026, following positive results from the Phase 1/2 STAAR study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.